Neuroone Medical Technologies (NMTC) Cash & Equivalents (2017 - 2026)

Neuroone Medical Technologies' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• Quarterly Cash & Equivalents rose 112.08% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 112.08% YoY) and the FY2025 annual result came in at $6.6 million, up 350.01% from the prior year.
• Cash & Equivalents was $2.8 million for Q1 2026 at Neuroone Medical Technologies, down from $3.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $12.9 million in Q1 2022 and bottomed at $1.1 million in Q4 2024.
• A 5-year average of $4.7 million and a median of $3.6 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 72.57% — and 2025, when it soared 393.83%.
• Neuroone Medical Technologies' Cash & Equivalents stood at $4.7 million in 2022, then sank by 42.56% to $2.7 million in 2023, then plunged by 57.69% to $1.1 million in 2024, then soared by 213.98% to $3.6 million in 2025, then decreased by 21.38% to $2.8 million in 2026.
• Business Quant data shows NMTC's Cash & Equivalents at $2.8 million in Q1 2026, $3.6 million in Q4 2025, and $6.6 million in Q3 2025.